康泰医学实控人拟减持 2024转亏2020上市2募资共11亿

Summary of Key Points Core Viewpoint - 康泰医学's controlling shareholder, 胡坤, plans to reduce his stake in the company by up to 12 million shares, which is approximately 2.99% of the total share capital, through both centralized bidding and block trading methods [1] Group 1: Shareholder Reduction Plan - 胡坤 currently holds 188,189,252 shares, representing 46.84% of the total share capital [1] - The reduction will occur within three months starting from fifteen trading days after the announcement [1] - The reduction includes a maximum of 4 million shares through centralized bidding and 8 million shares through block trading [1] Group 2: Financial Performance - In 2024, 康泰医学 reported a revenue of 480 million yuan, a decrease of 35.76% compared to 2023 [4][5] - The net profit attributable to shareholders was -77.9 million yuan, a decline of 147% from the previous year [4][5] - The net cash flow from operating activities was 62.34 million yuan, down 65.56% year-on-year [4][5] Group 3: Fundraising Activities - 康泰医学 has raised a total of 1.117 billion yuan since its listing, including 4.17 billion yuan from its initial public offering [2][3] - The company issued 7 million convertible bonds in 2022, raising 700 million yuan, with a net amount of approximately 688 million yuan after expenses [3]